NRIX

Nurix TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$26.00

Analysis reference price unavailable

Analysis 2026-05-05 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$18.00

Analysis reference price unavailable

Analysis 2026-05-05 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$10.00

Analysis reference price unavailable

Analysis 2026-05-05 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-05

AI commentary

Primary-source tone is constructive on pipeline progress but not cleanly bullish on fundamentals: the April 8 update highlighted multiple 2026 catalysts and a sizable cash balance, yet revenue declined, spending rose, and the 10-Q kept the long-term funding gap explicit [#8-K-2026-04-08] [#10-Q-2026-04-08]. Recent media coverage in the packet is thin and mostly non-primary, with no robust analyst-revision set attached, so this remains a cautious monitoring view. Deterministic scoring also leans neutral with modestly negative forward returns and only mid-level evidence quality.

RankAlpha Sentiment Codex - 2026-05-05

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventMid-2026 Phase 3 bexobrutideg trial startHigh impact

Nurix said it plans to initiate the global randomized DAYBreak CLL-306 confirmatory Phase 3 trial by midyear 2026 to support full approval for bexobrutideg in relapsed/refractory CLL, making trial-start execution the clearest near-term pipeline checkpoint [#8-K-2026-04-08].

2026-09-30event2026 clinical data flow from NX-5948-301High impact

Nurix said updated data from the NX-5948-301 Phase 1a/1b study are anticipated at upcoming medical meetings throughout 2026; positive efficacy or tolerability updates could improve confidence in earlier-line CLL positioning, while muted data would likely pressure sentiment [#8-K-2026-04-08].

2026-12-31catalystImmunology expansion via 2026 IND targetHigh impact

Management is targeting a 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications using a new tablet formulation, which could broaden the platform beyond oncology if the healthy-volunteer work supports filing [#8-K-2026-04-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-05 • Updated nightlySource: Internal modelMethodology